Welcome to the e-CCO Library!

P0619: Comparative efficacy of all available pharmaceutical therapies for moderate to severe Crohn’s disease: a systematic review and network meta-analysis.
Year: 2025
Source: ECCO'25
Authors: Versteeghx7x7x7 M.(1)*;Idemax7x7x7 D.(2);Huygensx7x7x7 S.(1);Jenniskensx7x7x7 K.(2);Pierikx7x7x7 M.(3);Römkensx7x7x7 T.(4);van Schaikx7x7x7 F.(5);Wahabx7x7x7 P.(6);Huis in 't veldx7x7x7 L.(2);Kustersx7x7x7 M.(7);van der Braakx7x7x7 K.(2);Hooftx7x7x7 L.(2);Damenx7x7x7 J.(2);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P061: Circulating inflammatory protein and cellular profiles at time of diagnosis classify inflammatory bowel disease patients according to their underlying immune response and clinical disease course
Year: 2022
Source: ECCO'22
Authors: Heredia, M.(1);Charrout, M.(2);Klomberg, R.C.W.(3);Aardoom, M.A.(3);Jongsma, M.M.E.(3);Kemos, P.(4);van Haaften, D.H.(1);Tuk, B.(1);van Berkel, L.A.(1);Bley Folly, B.(1);Mahfouz, A.(2,5);Reinders, M.J.T.(2);Ruemmele, F.(6);Croft, N.(4);Escher, J.C.(3);de Ridder, L.(3);Samsom, J.N.(1);
Created: Friday, 11 February 2022, 3:52 PM
P061: Creeping fat contains a unique T-cell compartment with potential impact on intestinal inflammation
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. I. Kredel*1, L. J. Jödicke1, A. A. Kuehl1, I. Freise1, J. Gröne2, B. Siegmund1

Created: Friday, 22 February 2019, 9:49 AM
P061: Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – IBD Character
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Adams A.*1, Kalla R.1, Vatn S.2, Bonfiglio F.3, Nimmo E.1, Kennedy N.1, Ventham N.1, Vatn M.2, Ricanek P.4, Bergemalm D.5, Halfvarson J.5, Söderholm J.6, Pierik M.7, Törkvist L.8, Gomollόn F.9, Gut I.10, Jahnsen J.2, Satsangi J.1 IBD Character Consortium

Created: Wednesday, 20 February 2019, 10:36 AM
P061: Immune cell infiltrations of myenteric plexus in IBD – characterization and implications
Year: 2021
Source: ECCO'21 Virtual
Authors: Wiese, J.J.(1);Fascì , A.(1);Kühl, A.A.(1);Siegmund, B.(1);Prüß, M.S.(1);Schumann, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P061: Probiotic kimchi prevented colitis-associated cancer
Year: 2018
Source: ECCO '18 Vienna
Authors:

K.B. Hahm1*, Y.M. Han2, J.M. Park2

Created: Thursday, 21 February 2019, 9:14 AM
P061: Response to anti-α4β7 therapy in Ulcerative colitis is associated with lymphoid aggregate attrition through impaired recruitment of naïve lymphocytes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Canales-Herrerias, P.(1)*;Uzzan*, M.(1);Seki*, A.(1);Czepielewski, R.S.(2);Verstockt, B.(3);Dunn, A.(1);Dai, D.(1);Ko, H.M.(4);Furtado, G.C.(5);Tokuyama, M.(1);Tankelevich, M.(1);Meringer, H.(1);Cossarini, F.(1);Jha, D.(1);Paulsen, J.D.(6);Nakadar, M.Z.(6);Wong, J.(6);Sharma, K.(1);Rosenstein, A.(1);Dawson, T.(7);Singh, H.(1);Lim, J.(8);Lira, S.A.(5);Yajnik, V.(9);Reboldi, A.(10);Petralia, F.(11);Vermeire, S.(3);Polydorides, A.D.(6);Randolph, G.J.(2);Colombel , J.F.(1);Mehandru, S.(1);
Created: Friday, 14 July 2023, 10:48 AM
P061: Succinate promotes EMT in intestinal epithelial cells through SUCNR1: Relevance in fistula development
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Cosin-Roger*1,2, D. Ortiz-Masia3, M. Aragón-Borrego1, L. Gisbert-Ferrándiz1, S. Calatayud1, M. D. Barrachina1

Created: Friday, 22 February 2019, 9:41 AM
P062 Dose-dependent differential effects of vedolizumab therapy on adhesion of regulatory and effector T cells
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Becker, M. Wiendl, A. Schulz-Kuhnt, I. Atreya, R. Atreya, M. Neurath, S. Zundler

Created: Thursday, 30 January 2020, 10:12 AM
P0620: Long-term impact of early medical prevention of postoperative recurrence on second intestinal resections in patients with Crohn’s Disease. Data from the ENEIDA registry.
Year: 2025
Source: ECCO'25
Authors: Piñerox7x7x7 G.S.(1)*;Nosx7x7x7 P.(2);Ricartx7x7x7 E.(3);Calafat x7x7x7 M.(1);Riestra x7x7x7 S.(4);Mesonerox7x7x7 F.(5);Iglesias-Floresx7x7x7 E.(6);Pascual-Morenox7x7x7 I.(7);Verax7x7x7 I.(8);Martín-Arranzx7x7x7 M.D.(9);De Castrox7x7x7 L.(10);Taxonerax7x7x7 C.(11);Riverox7x7x7 M.(12);Guardiolax7x7x7 J.(13);Arranz Hernandezx7x7x7 L.(14);Arias Garciax7x7x7 L.(15);Varelax7x7x7 P.(16);Giordanox7x7x7 A.(17);Gisbertx7x7x7 J.P.(18);Barriox7x7x7 J.(19);Calvetx7x7x7 X.(20);Gutiérrez-Casbasx7x7x7 A.(21);García-Lópezx7x7x7 S.(22);Gargallo-Puyuelox7x7x7 C.J.(23);Huguetx7x7x7 J.M.(24);Moralejax7x7x7 I.(25);Pérez-Callex7x7x7 J.L.(26);Bujandax7x7x7 L.(27);Zabanax7x7x7 Y.(28);Ramosx7x7x7 L.(29);Sierra x7x7x7 M.(30);Carpiox7x7x7 D.(31);Barreiro-de-Acostax7x7x7 M.(32);Lorente x7x7x7 R.(33);Bermejox7x7x7 F.(34);González-Lamax7x7x7 Y.(35);Navarro-Llavatx7x7x7 M.(36);Márquezx7x7x7 L.(37);Mañosax7x7x7 M.(1);Domènechx7x7x7 E.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0621: Effectiveness and Safety of Induction Therapy with Upadacitinib for the Treatment of Perianal Crohn’s Disease : Real-World Data from a GETAID Multicentre Cohort Study.
Year: 2025
Source: ECCO'25
Authors: Richardx7x7x7 N.(1)*;Altweggx7x7x7 R.(2);Seksikx7x7x7 P.(3);Nanceyx7x7x7 S.(4);Nachuryx7x7x7 M.(5);Lahariex7x7x7 D.(6);Amiotx7x7x7 A.(7);Vuittonx7x7x7 L.(8);Peyrin-Birouletx7x7x7 L.(9);Allezx7x7x7 M.(10);Rouillonx7x7x7 C.(11);Coffinx7x7x7 B.(12);Pelletierx7x7x7 A.L.(13);Uzzanx7x7x7 M.(14);Amilx7x7x7 M.(15);Hupéx7x7x7 M.(16);Fumeryx7x7x7 M.(17);Bozonx7x7x7 A.(2);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0622: Total emulsifier intakex7x7x7 but not ultra-processed food consumption is higher in patients with Inflammatory Bowel Disease compared to healthy controls
Year: 2025
Source: ECCO'25
Authors: Wellensx7x7x7 J.(1)*;Debrauwerex7x7x7 M.(2);Hoekxx7x7x7 S.(1);Vanderstappenx7x7x7 J.(1);De Maegdx7x7x7 E.(2);Vissersx7x7x7 E.(2);Ferrantex7x7x7 M.(1);Verstocktx7x7x7 B.(1);Vermeirex7x7x7 S.(1);Sabinox7x7x7 J.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0623: Vedolizumab clearance as a predictor of remission in inflammatory bowel disease: a real-world pharmacokinetic study
Year: 2025
Source: ECCO'25
Authors: Markovicx7x7x7 S.(1);Kraljx7x7x7 D.(1)*;Knezevic Ivanovski x7x7x7 T.(1);Kalabax7x7x7 A.(1);Odanovicx7x7x7 O.(1);Homsekx7x7x7 A.(2);Svorcanx7x7x7 P.(1);Vucicevicx7x7x7 K.(2);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0624: Adherence to a Care Pathway for Inflammatory Bowel Disease in the Southwest region of the Netherlands
Year: 2025
Source: ECCO'25
Authors: Visserx7x7x7 E.(1x7x7x72)*;Allersx7x7x7 S.(3);van Linschotenx7x7x7 R.(4);Bodelierx7x7x7 A.(5);Fitzpatrickx7x7x7 C.(6);de Jongx7x7x7 V.(7);Vermeulenx7x7x7 H.(8);Verweijx7x7x7 E.(9);van der Wielx7x7x7 S.(10);van der Horstx7x7x7 D.(11);van der Woudex7x7x7 C.J.(12);van Noordx7x7x7 D.(1);Westx7x7x7 R.L.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0625: Impact of TMPT genotype on Azathioprine side effects and durability in a cohort of pediatric patients with Inflammatory Bowel Diasease: a real life study.
Year: 2025
Source: ECCO'25
Authors: Di Sariox7x7x7 F.(1)*;Galeazzix7x7x7 T.(2);Castaldox7x7x7 P.(3);Magix7x7x7 S.(3);Franceschini x7x7x7 E.(4);Gattix7x7x7 S.(2);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0626: One year outcomes of upadacitinib in Crohn’s disease in a large real-world cohort.
Year: 2025
Source: ECCO'25
Authors: Ramos Belinchonx7x7x7 C.(1)*;Plevrisx7x7x7 N.(1);Elfordx7x7x7 A.(1);Grosx7x7x7 B.(1x7x7x72);Constantine-Cookex7x7x7 N.(3x7x7x74);Arnottx7x7x7 I.D.(1);Leesx7x7x7 C.W.(1x7x7x73);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0627: Pharmacokineticsx7x7x7 Pharmacodynamicsx7x7x7 Safetyx7x7x7 and Efficacy of Oral Resolvin E1-based Therapy in Inflammatory Bowel Disease (IBD): Translating Resolvin E1 Activation of BLT1 in Experimental Models to Healthy Volunteers
Year: 2025
Source: ECCO'25
Authors: Danesex7x7x7 S.(1)*;Siegmundx7x7x7 B.(2);Peyrin-Birouletx7x7x7 L.(3);Verstocktx7x7x7 B.(4);Dubinskyx7x7x7 M.(5);Newmanx7x7x7 R.(6);Thomasx7x7x7 H.(7);Guttendorfx7x7x7 R.(7);Lipperx7x7x7 R.(8);Steinbergx7x7x7 J.(9);Paperiellox7x7x7 B.(9);Jenningsx7x7x7 T.(9);Jordanx7x7x7 D.(9);Parkinsonx7x7x7 J.(9);Mathiasx7x7x7 G.(9);Sandsx7x7x7 B.(10);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0628: Patient preferences towards treatment attributes in Inflammatory Bowel Disease: a Brazilian cohort study
Year: 2025
Source: ECCO'25
Authors: Argollox7x7x7 M.(1)*;Queirozx7x7x7 N.(2);Kurtz de Mellox7x7x7 M.(3);Senrax7x7x7 J.(4);Rosax7x7x7 B.(4);Barretox7x7x7 T.(5);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0629: A scoping review of evidence-based dietary guidance and guidelines published by national and international organisations on Inflammatory Bowel Disease
Year: 2025
Source: ECCO'25
Authors: Dimakisx7x7x7 I.K.(1);Kapsoritakisx7x7x7 A.(1);Argyrioux7x7x7 K.(1);Manolakisx7x7x7 A.(1);Grammatikopouloux7x7x7 M.(1);Gkikasx7x7x7 K.(2);Gerasimidisx7x7x7 K.(2);Androutsosx7x7x7 O.(3);Svolosx7x7x7 V.(4)*;
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P062: 31P MRS and MRI phenotyping of muscle metabolic quality in IBD fatigue
Year: 2022
Source: ECCO'22
Authors: Mcging, J.(1,2);Nicholas, R.(2);Serres, S.(3);Greenhaff, P.(3,4,5);Francis, S.(2);Moran, G.W.(1,5);
Created: Friday, 11 February 2022, 3:52 PM